Download Docs
Export

ALYGLO

90160114 | Trademark

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed Sept. 4, 2020
Serial No. 90160114
Examining Attorney MATTHEW PATTER HOWELL
Interlocutory Attorney ANDREW P BAXLEY
Class Blood plasma derivatives for medical purposes, namely, immune globulins including Rh immune globulin; Immunoglobulin preparations, namely, pharmaceutical immunoglobulin preparations for diagnosis of primary humoral immunodeficiency, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome, severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), for preventing primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP), and for treatment of primary humoral immunodeficiency, Kawasaki disease, Guillain-Barre syndrome, common variable immune deficiency, X-linked agammaglobulinemia (XLA), hyper immunoglobulin M syndromes, Wiskott Aldrich Syndrome and severe combined immune deficiency (SCID), agammaglobulinemia, hypogammaglobulinemia, cardiovascular disease, inflammatory diseases, immunological disorders, bacterial infections, acute serious bacterial infection, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP); all the foregoing for patient treatment by injection or in liquid form by health professional; 005; 006; 018; 044; 046; 051; 052
ALYGLO
Status A fourth request for extension of time to file a Statement of Use has been granted.
Opposition 91272343
NovartisAG v. Green Cross Corporation
  • Green Cross Corporation;
  • NovartisAG;
Opposition 90160114
NOVARTIS AG v. Green Cross Corporation
  • Green Cross Corporation;
  • NOVARTIS AG;
Last Updated: 1 month, 2 weeks ago
Filing Date # Docket Text